nsPFA Navigation (Pulse Biosciences)
Cardiac Arrhythmias
Pre-clinicalActive
Key Facts
About CardioNXT
CardioNXT is a US-based, private medical device company founded in 2015, specializing in 3D mapping and navigation systems for cardiac ablation procedures. Its core iMap System platform is FDA 510(k) cleared and is being developed to navigate novel pulsed field ablation (PFA) catheters from major players like Boston Scientific and Medtronic, as well as its own sensor-enabled diagnostic catheters. The company is led by a seasoned team with prior successful exits in the medical device space, including the co-founder of Veran Medical Technologies (acquired by Olympus). CardioNXT operates in the high-growth cardiac ablation market, positioning itself as an enabling navigation platform for the next wave of PFA technologies.
View full company profileTherapeutic Areas
Other Cardiac Arrhythmias Drugs
| Drug | Company | Phase |
|---|---|---|
| Platform Extension (e.g., Cardioneuroablation) | inHEART | Development/Exploration |
| Cardiac Arrhythmia Program | Current Surgical | Research |
| MicroPort EverPace™ PulseMagic™ TrueForce® PFA Catheter | MicroPort | NMPA Approved |
| Aveir DR Dual-Chamber Leadless Pacemaker | Abbott | Clinical Investigation |